oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes 🔴Cardiovascular with by severity of chronic kidney disease diabetes: the FLOW trial⤵️ 🔹Semaglutide significantly reduced the risk of CV death/MI/stroke regardless of baseline CKD severity in participants Retrospective Comparative Study of Oral
Description
Our patients receiving tirzepatide have often seen improvements in metabolic markers such as blood sugar control, waist circumference, and cholesterol levels
Dr Tee was a fantastic doctor
Supervised strength training is the direct answer to all of it
That's your body talking
So what is inside instead
What we know is that the active ingredient is the same, the mechanism of action is identical, and the clinical evidence for semaglutides effectiveness comes from the molecule itself rather than the delivery format
